Potent (<10nM) and subtype-selective (>1'000-fold) PPARγ agonist which does not contain a thiazolidinedione moiety. The glucose-lowering effect of GW1929 in rats is 100-fold more potent than that of troglitazone (Prod. No. BML-GR210).
Product Details
| Alternative Name: | N-(2-Benzoylphenyl)-L-tyrosine PPARγ Agonist, (2S)-((2-Benzoylphenyl)amino-3-[4-[2-(methylpyridin-2-ylamino)ethoxy]phenyl)propionic acid |
| |
| Formula: | C30H29N3O4 |
| |
| MW: | 495.6 |
| |
| CAS: | 196808-24-9 |
| |
| Purity: | ≥97% (HPLC) |
| |
| Appearance: | Off-white to yellow crystalline solid. |
| |
| Solubility: | Soluble in DMSO or methanol. |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | +4°C |
| |
| Handling: | Protect from light. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
15-Deoxy-{delta}12,14-prostaglandin j2 inhibits interleukin-1{beta}-induced nuclear factor-{kappa}b in human amnion and myometrial cells: mechanisms and implications: T.M. Lindström & P.R. Bennett; J. Clin. Endocrinol. Metab.
90, 3534 (2005),
Abstract;
Full Text
Superoxide anion-dependent Raf/MEK/ERK activation by peroxisome proliferator activated receptor gamma agonists 15-deoxy-delta(12,14)-prostaglandin J(2), ciglitazone, and GW1929: W.C. Huang, et al.; Exp. Cell Res.
277, 192 (2002),
Abstract;
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents: B.R. Henke, et al.; J. Med. Chem.
41, 5020 (1998),
Abstract;
Related Products
